Against the backdrop of continuous advancements in lymphoma treatment in China, domestic biosimilars are steadily expanding their clinical boundaries.
On April 9, Shanghai Henlius Biotech announced that its rituximab injection Hanlikang® (HLX01) has received approval from the National Medical Products Administration for two new indications in non-Hodgkin lymphoma (NHL), further...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek